The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Reinaldo Bulgarelli Bestetti, Rosemary Aparecida Furlan Daniel

Abstract


Chronic Heart Failure (CHF) affects about half patients with Chagas cardiomyopathy. Outcome of CHF secondary to Chagas cardiomyopathy is relentless with an annual mortality approaching 20%, which is higher than that observed in non-Chagas disease heart failure. The pathophysiology of Chagas disease is similar to that found in non-Chagas disease heart failure with a marked activation of the neurohormonal system. No randomized trial has been conducted in patients with Chagas cardiomyopathy with CHF to assess the effect of a drug on mortality of such patients. Therefore, the treatment of CHF secondary to Chagas cardiomyopathy relies on drugs prescribed to patients with non-Chagas disease heart failure. Patients with Chagas disease heart failure have been classified into stages A to D according to the American College of Cardiology/American Heart Association.  Little can be done to patients in the stage A of CHF, except for treatment of comorbidities. In patients in the stage B of CHF, aldosterone receptor antagonist, angiotensin converting enzyme inhibitors (ACEI), and Betablockers (BB) can be indicated. In patients in the stage C of CHF, the same drugs are of value. In addition, diuretics, digoxin, angiotensin receptor blockers to patients intolerant to ACEI have also been used.  Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator may have indications similar to that of non-Chagas disease patients. In stage D of CHF, heart transplantation is a valid option for patients with this condition. 


Keywords


Key words; Chagas disease; heart failure; sudden cardiac death; Betablockers; Trypanosoma cruzi; angiotensin converting enzyme inhibitor.

Full Text:

PDF HTML

References


Anonymous. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wky Epidemiol Rec. 2015 Feb; 90 (6): 33-44. PMID: 25671846

Bestetti RB, Cardinalli-Neto A. Sudden cardiac death in Chagas' heart disease in the contemporary era. Int J Cardiol. 2008 Dec; 131 (1): 9-17. doi: 101016/j.ijcard.2008.05.024

Samuel J, Oliveira M, Correa De Araujo RR, Navarro MA, Muccillo G. Cardiac thrombosis and thromboembolism in chronic Chagas' heart disease. Am J Cardiol. 1983 Jul ; 52 (1):147-51. PIMD: 6858902

Bestetti RB, Restini CB. Precordial chest pain in patients with chronic Chagas disease. Int J Cardiol. 2014 Sep; 176 (2): 309-14. doi: 10.1016/j.ijcard.2014.07.112

Gonçalves JGF, Silva VJD, Borges MCC, Prata A, Correia D. Mortality indicators among chronic Chagas patients living in an endemic area. Int J Cardiol. 2010 Sep; 143 (3): 235-42. doi: 10.1016/j.ijcard.2009.02.011

Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J. 2008 Sep; 156 (3): 422-30. doi: 10.1016/j.ahj.2008.04.023.

Bestetti RB, Dalbo CM, Arruda CA, Correia Filho D, Freitas OC. Predictors of sudden cardiac death for patients with Chagas' disease: a hospital-derived cohort study. Cardiology. 1996 Nov-Dec; 87 (6): 481-7. PIMD: 8904674.

Theodoropoulos TA, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol. 2008 Aug;128 (1): 22-9. doi: 10.1016/j.ijcard.2007.11.057.

Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997 Jul; 60 (2): 187-93. PMID: 9226290.

Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol. Jul 2005; 102 (2): 239-47. PMID: 15982491.

Pereira Nunes M do C, Barbosa MM, Ribeiro AL, Amorim Fenelon LM, Rocha MO. Predictors of mortality in patients with dilated cardiomyopathy: relevance of Chagas disease as an etiological factor. Rev Esp Cardiol. 2010 Jul; 63 (7): 788-97. PMID: 20609312.

Barbosa AP, Cardinalli Neto A, Otaviano AP, Rocha BF, Bestetti RB. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq Bras Cardiol. 2011 Dec; 97 (6): 517-25. PMID: 22030565.

Vilas Boas LG, Bestetti RB, Otaviano AP, Cardinalli-Neto A, Nogueira PR. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy. Int J Cardiol. 2013 Jul; 167(2): 486-90. doi: 10.1016/j.ijcard.2012.01.033.

Bestetti RB, Otaviano AP, Fantini JP, Cardinalli-Neto A, Nakazone MA, Nogueira PR. Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertension. Int J Cardiol. 2013 Oct; 168 (3): 2990-1. doi: 10.1016/j.ijcard.2013.04.015.

Paulus WJ, Tshöepe C, Sanderson JE, Ruscono C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulener G, Leite-Moreira A, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology. Eur Heart J. 2007 Oct; 28 (20): 2539-50. PMID: 17428822.

Espinosa R, Carrasco HÁ, Belandria F, Fuenmayor AM, Molina C, Gonzalez R, Martinez O. Life expectancy analysis in patients with Chagas disease: prognosis after one decade (1973-1983). Int J Cardiol. 1985 May; 8 (1): 45-56. PMID: 3997291.

Pazin-Filho A, Romano MMD, Almeida-Filho OC, Furuta MS, Viviani LF, Schimidt A, Marin-Neto JA, Maciel BC. Minor segmental wall motion abnormalities detected in patients with Chagas disease have adverse prognostic implications. Br J Med Biol Res. 2006 Apr; 39 (4): 483-7. PMID: 16612471.

Petti MA, Viotti R, Armenti A, Bertocchi G, Lococco B, Alvarez MG, Vigliano C. Predictors of heart failure in chronic chagasic cardiomyopathy with asymptomatic left ventricular dysfunction. Rev Esp Cardiol 2008 Feb; 61 (2): 116-22. PMID: 18364179.

Dias E, Laranja FS, Nobrega G. Doença de Chagas. Mem Inst O Cruz. 1945; 43: 495-581

Bestetti RB, Ramos CP, Godoy RA, Oliveira JS. Chronic Chagas' heart disease in the elderly: a clinicopathologic study. Cardiology. 1987;74 (5): 344-51. PMID: 3652079.

Ayub-Ferreira SM, Mangini S, Issa VS, Cruz FD, Bacal F, Guimarães GV, Chizzola PR, Conceição-Souza GE, Marcondes-Braga FG, Bocchi EA. Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective Trial. PLoS Negl Trop Dis. 2013 Apr; 7: e2176. doi: 10.1371/journal.pntd.0002176.

Andrade JP, Marin-neto JA, paola AAV, Oliveira GMM, Bacal F, Bocchi EA, Almeida DR, Fragata-Filho AA, Moreira MCV, Xavier SS, Oliveira-Júnior W, Dias JCP, et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino-Americana para o diagnóstico e tratamento da Cardiopatia Chagásica Crônica. Arq Bras Cardiol. 2011; 97 (2suppl.3); 1-48. PIMD: 21952638.

McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickenstein K, Falk V, Filippatos G, Fonseca C, Sanchez MAG, Jaarsma T, Kober L, lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012.Eur Heart J. 2012 Jul; 33 (14): 1787-1847. doi: 10.1093/eurheartj/ehs104.

Bocchi EA, Marcondes-Braga FG, Bacal F, Ferraz AG, Albuquerque D, Rodrigues D et al. Sociedade Brasileira de Cardiologia. Atualização da Diretriz Brasileira de Insuficiência Cardíaca Crônica -2012. Arq Bras Cardiol. 2012 Jan; 98 (1 suppl.1); 1-33. PMID: 22392082.

Yancy C, Jessup MJ, Bozkurt B, Butler J, Casey-Jr DE, Drazner MH, Fonarow GC, geraci AS, Horwich T, Januzzi JL, Johson MR, kasper EK, levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, petertson PN, riefgel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline fopr the management of heart failure. J Am Coll Cardiol. Oct 2013; 62 (16): e147-e238.

Bestetti RB, Cardinalli-Neto A, Otaviano AP, Nakazone MA, Bertolino ND, Nogueira PR. Hyponatremia in Chagas disease heart failure: Prevalence, clinical characteristics, and prognostic importance. Clin Trials Reg Sci Cardiol. 2015 Nov ; 11: 6–9. doi.org/10.1016/j.ctrsc.2015.09.003

Palmero HA, Caeiro TF, Iosa DJ. Effect of Chagas’ disease on arterial blood pressure. Am Heart J. 1979 Jan; 97 (1): 38-42. PMID: 103414.

Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997 Jul; 60 (2): 187-93. PIMD: 9226290.

Parra AV, Rodrigues V, Cancella S, Cordeiro JA, Bestetti RB. Impact of socioeconomic status on outcome of a Brazilian heart transplant recipients cohort. Int J Cardiol. 2008 Mar; 125 (1): 142-3. PMID: 17399819.

Câmara EJ, Cruz TR, Nassri JM, Rodrigues LE. Muscle magnesium content and cardiac arrhythmias during treatment of congestive heart failure due to chronic chagasic cardiomyopathy. Braz J Med Biol Res. 1986; 19 (1): 49-58. PMID: 3801726.

Albuquerque DC, Souza-Neto JD, Bacal F, Rohde LEP, Bernardez-Pereira S, Berwanger O, Almeida DR. I Registro Brasileiro de Insuficiência Cardíaca. Aspectos clínicos, qualidade assistencial e desfechos hospitalares. Arq Bras Cardiol. 2015 Jun; 104 (6): 433-42. doi: 10.5935/abc.20150031.

Lima MOM, Rocha MOC, Nunes MCP, Sousa L, Costa HS, Alencar MCN, Britto RR, Ribeiro ALP. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur J Heart Fail. 2010 Aug; 12 (8): 866-73. doi: 10.1093/eurjhf/hfq123.

Veiga MF, Rodrigues IF, Cardinalli-Neto A, Otaviano AP, da Rocha BF, Bestetti RB. Clinical course of patients with chronic systolic heart failure due to the association of Chagas disease and systemic arterial hypertension. Int J Cardiol. 2011 May; 19 (1): 149: 122-4. doi: 10.1016/j.ijcard.2011.01.090.

Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi- Jr A, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med 2015. Oct; 373 (14): 1295-306. doi: 10.1056/NEJMoa1507574.

Bellabarba G, Davila DF, Torres A, Donis JH, Gonzalez JC, Figueroa O, Vasquez CJ, Faddoul M, Khoury A. Plasma renin activity in chagasic patients with and without congestive heart failure. Int J Cardiol. 1994 Nov; 47 (1): 5-11. PMID: 7868285.

Davila DF, Bellabarba G, Hernandez L, Calmon G, Torres A, Donis JH, Barboza JS, Lemorvan C, Gonzalez JG. Plasma norepinephrine, myocardial damage and left ventricular systolic function in Chagas' heart disease. Int J Cardiol. 1995 Nov; 52 (2): 145-51. PMID: 8749874.

Bestetti RB1, Coutinho-Netto J, Staibano L, Pinto LZ, Muccillo G, Oliveira JS. Peripheral and coronary sinus catecholamine levels in patients with severe congestive heart failure due to Chagas' disease. Cardiology. 1995; 86 (3): 202-6. PMID: 7614491.

Negrão CE, Santos AC, Rondon MU, Franco FG, Ianni B, Rochitte CE, Braga AMFW, Oliveira-Jr MT, Mady C, Barretto ACP, Middlekauff HR. Muscle sympathetic nerve activity in patients with Chagas' disease. Int J Cardiol. 2009 Nov; 137 (3): 252–259. doi: 10.1016/j.ijcard.2008.06.093.

Bestetti RB, Ramos CP, Figuerêdo-Silva J, Sales-Neto VN, Oliveira JS. Ability of the electrocardiogram to detect myocardial lesions in isoproterenol induced rat cardiomyopathy. Cardiovasc Res 1987. Dec; 21 (12): 916-21. PMID: 3331969.

Ramires FJ, Salemi VM, Ianni BM, Fernandes F, Martins DG, Billate A, Neto EC, Mady C. Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst. 2006 Sep; 7 (3): 162-7. PMID: 17094053.

Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Int J Cardiol 2011. Sep; 151 (2) : 205-8. doi: 10.1016/j.ijcard.2010.05.033.

Roberti RR, martinez EE, Andrade JL, Araujo VL, Brito FS, Portugal OP, Horowitz SF. Chagas cardiomyopathy and captopril. Eur Heart J. 1992 Jul ; 13(7): 966-70. PMID: 1644089.

Szajnbok FEK, Barretto ACP, Mady C, Parga-Filho J, Gruppi C, Alfieri RG, da Luz PL, Pileggi F. Ação benéfica do enalapril sobre a função diastólica ventricular na miocardiopatia da doença de Chagas. Arq Bras Cardiol. 1993 Apr; 60 (4): 273-8. PMID: 8311739.

Botoni FA, Poole-Wilson P, Ribeiro ALP, Okonko DO, Oliveira BMR, Pinto AS, Teixeira MM, Teixeira-Jr AL, Reis AM, Dantas JBP, Ferreira CS, Tavares-Jr W, Rocha MOC. A randomized atrial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 2007 Apr; 153 (4): 544.e1-544.e8

Merit HF study group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999 Jun; 353 (9169): 2001-7. PMID: 10376614.

Davila DF, Angel F, Bellabarba GA, Donis JH. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol 2002 Oct; 85 (2-3): 255-60. PMID: 12208592.

Issa VS, Amaral AF, Cruz FD, Ferreira SMA, Guimarães GV, Chizzola PR, Souza GEC, Bacal F, Bocchi EA. B-blocker therapy and mortality of patients with Chagas cardiomyopathy. A subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010; 3 (1): 82-88. doi: 10.1161/CIRCHEARTFAILURE.109.882035.

Del Carlo CH, Cardoso JN, Ochia ME, Oliveira-Jr MT, Ramires JAF, Pereira-Barretto ACP. Temporal variation in the prognosis and treatment of advanced heart failure before and after 2000. Arq Bras Cardiol. 2014 May; 102 (5): 495-504. PMID: 24759950.

Packer M. Pathophysiology of heart failure. Lancet. 1992 Jul; 340 (8811): 88-95.

Cleland JG, Cohen-Solal A, Aguillar JC, Dietz R, Eastaugh J, Follat F, freemantle N, Gavazzi L, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, preda I, Swedberg K, Widimsky J. Improvement programme in evaluation and management. Study group on diagnosis of the working group on heart failure of the European Society of Cardiology. Lancet 2002 Nov; 360 (9346): 1631-9. PMID: 12457785.

Network investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison study. Eur Heart J 1998 Mar; 19 (3): 481-9. PMID: 9568453.

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, Lisinopril, on morbidity or mortality in chronic heart failure. Atlas study group. Circulation 1999 Dec; 100 (23): 2312-8. PMID: 10587334.

Barretto ACP, Pileggi F. Digital na Cardiopatia Chagasica. Arq Bras Cardiol. 1982 Apr;38 (5):283-9. PMID: 7168661.

Ferrari SJ, Bestetti RB, Cardinalli-Neto A, Bortoluzzi TB. Digoxin serum levels in patients with Chagas’ cardiomyopathy heart failure. Rev Soc Bras Med Trop. 2010; 43: 496-99.

Cardinalli-Neto A, Lorga-Filho AM, Silva EF, Lima RP, Palmegiani E, Bestetti RB. Clinical predictors of inducible sustained ventricular tachycardia during electrophysiologic study in patients with chronic Chagas' heart disease. IJC Heart & Vasculature. 2015 Dec; 9 (4): 85–8. http://dx.doi.org/10.1016/j.ijcha.2015.10.001.

Carod-Artal FJ, Vargas AP, Horan TA, Nunes LGN. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas’ disease. Stroke. 2005 May; 36 (5): 965-70. PMID: 1584889.

Souza AS, Xavier SS, Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic stroke in Chagas disease. Arq Bras Cardiol 2008 Nov; 91 (5):280-4. PMID: 19142374.

Araújo EF, Chamlian EG, Peroni AP, Pereira WL, Gandra SMA, Rivetti LA. Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up. Rev Bras Cir Cardiovasc 2014 (Jan-Mar); 29 (1): 31-6. PMID: 24896160.

Bestetti RB. Cardiac resynchronization therapy for patients with chronic systolic heart failure secondary to Chagas cardiomyopathy in the 21st century. Rev Bras Cir Cardiovasc 2014 Jan-Mar; 29 (1):4-6. PMID: 248961174.

Cardinalli-Neto A, Nakazone MA, Grassi LV, Tavares BG, Bestetti RB. Implantable Cardioverter-Defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy. Int J Cardiol. 2011 Jul; 150(1): 94-5. doi: 10.1016/j.ijcard.2011.03.036.

Ribeiro Dos Santos R, Rassi S, Feitosa G, Grecco OT, Rassi-Jr A, da Cunha AB, de Carvalho VB, Guarita-Souza LC, de Oliveira W Jr, Tura BR, Soares MB,Campos de Carvalho AC. Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial. Circulation. 2012 May; 125 (20): 2454-61. doi: 10.1161/CIRCULATIONAHA.111.067785.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v7i0.217

Copyright (c) 2016 Reinaldo Bulgarelli Bestetti, Rosemary Aparecida Furlan Daniel

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.